Hims & Hers Stock Draws Investor Attention After Tumbling 7% Here's What Happened

2025-09-16 03:15:36

(MENAFN- AsiaNet News)

Shares of Hims & Hers Health (HIMS) slumped 7% on Tuesday after the U.S. Food and Drug Administration (FDA) sent a letter to the company CEO regarding the sale of compounded drug products.

In the letter dated September 9, the agency alleged that the company's claims concerning compounded Semaglutide products, used for weight loss, are“false or misleading.” The FDA also noted that this is a violation of certain sections of the Federal Food, Drug, and Cosmetic Act.

The FDA pointed out that compounded drug products are not approved by it.“Your claims imply that your products are the same as an FDA-approved product when they are not,” the letter said, while urging the company to take immediate action to address violations. A failure to adequately address any violation may result in legal action without further notice, it added.

Get updates to this developing story <directly on Stocktwits.

MENAFN16092025007385015968ID1110070801

Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.